Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease

被引:5
作者
Wang, Jing [1 ]
Shen, Na [1 ]
Shen, Xuxing [1 ]
Zhang, Run [1 ]
Jin, Yuanyuan [1 ]
Li, Jianyong [1 ]
Chen, Lijuan [1 ,2 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Hematol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol,Collaborat Innovat Ctr Canc Personali, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
Multiple myeloma; extramedullary disease; clinical characteristics; prognostic model; STEM-CELL TRANSPLANTATION; HIGH-FREQUENCY; RISK; THERAPY; FEATURES; IMPACT; ERA; PLASMACYTOMAS; CARFILZOMIB; PROGRESSION;
D O I
10.1080/07853890.2023.2281657
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Extramedullary disease (EMD) is an unusual event in patients with MM. This study aimed to assess the prognostic impact of EMD and develop an EMD-based risk model to estimate the survival of patients with newly diagnosed multiple myeloma (NDMM).Methods: A total of 518 patients were enrolled in this study, of which 121 presented with EMD at the initial diagnosis. Patients were divided into non-EMD, extramedullary-bone-related (EM-B) and extramedullary-extraosseous (EM-E) groups. Clinical characteristics were compared using the chi-squared test or Fisher's exact test. Survival curves were plotted using the Kaplan-Meier method, and a nomogram was constructed based on the Cox proportional hazards model.Results: Compared to patients without EMDs, patients with EM-E were younger (p = 0.028), and those with EM-B had less renal damage (p < 0.001). The EM-E group had the worst progression-free survival (PFS) and overall survival (OS). In addition, patients with multiple sites of EMD invasion or high Ki67 expression had poor OS. Lenalidomide-based treatment showed the worst outcome, and autologous stem cell transplantation (ASCT) remarkably improved the survival of patients with EMD. A prognostic model (MM prognostic index, MM-PI) comprising lactate dehydrogenase (LDH), circulating plasma cells (CPC), del(17p), and type of extramedullary involvement was developed, and a 4-factor nomogram.Conclusions: We established a risk model incorporating extramedullary disease that provides accurate and individualized survival estimates for patients with NDMM.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Disease staging according to international scoring system in newly diagnosed patients with multiple myeloma
    Shaikh, Saira Parveen
    Irfan, Syed Muhammad
    Sheikh, Sadia Sultan
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (01) : 90 - 94
  • [32] 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study
    Shuang Gao
    Fei Dong
    Ping Yang
    Yingtong Chen
    Yanfang Wang
    Jing Wang
    Yanyan Shi
    Hongmei Jing
    [J]. Annals of Hematology, 2024, 103 : 1979 - 1987
  • [33] Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease
    Tucker, Susan M.
    Zaihra, Tasneem
    [J]. ORBIT-THE INTERNATIONAL JOURNAL ON ORBITAL DISORDERS-OCULOPLASTIC AND LACRIMAL SURGERY, 2023, : 603 - 611
  • [34] Impact of 18F-FDG PET/CT as a valuable prognostic tool for the newly diagnosed multiple myeloma with extramedullary disease
    Baek, Dong Won
    Jung, Sung Hoon
    Cho, Hee Jeong
    Hong, Chae Moon
    Sohn, Sang Kyun
    Moon, Joon Ho
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E196 - E197
  • [35] Survival trends and prognostic factors for patients with extramedullary plasmacytoma: A population-based study
    Shen, Xuxing
    Zhang, Lina
    Wang, Jing
    Chen, Lijuan
    Liu, Shu
    Zhang, Run
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Time to plateau as a predictor of survival in newly diagnosed multiple myeloma
    Mellors, Patrick W.
    Binder, Moritz
    Buadi, Francis K.
    Lacy, Martha Q.
    Gertz, Morie A.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam
    Kourelis, Taxiarchis
    Warsame, Rahma
    Zeldenrust, Steven R.
    Lust, John A.
    Leung, Nelson
    Go, Ronald S.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 889 - 894
  • [37] Extramedullary disease in multiple myeloma - controversies and future directions
    Sevcikova, Sabina
    Minarik, Jiri
    Stork, Martin
    Jelinek, Tomas
    Pour, Ludek
    Hajek, Roman
    [J]. BLOOD REVIEWS, 2019, 36 : 32 - 39
  • [38] New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients
    van de Donk, Niels W. C. J.
    Lokhorst, Henk M.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (12) : 1569 - 1573
  • [39] Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients
    Kim, M. K.
    Suh, C.
    Lee, D. H.
    Min, C. -K.
    Kim, S. J.
    Kim, K.
    Moon, J. H.
    Yoon, S. S.
    Lee, G. -W.
    Kang, H. J.
    Kim, S. -H.
    Choi, C. W.
    Eom, H. S.
    Kwak, J. -Y.
    Kim, H. J.
    Mun, Y. -C.
    Bang, S. -M.
    Lee, K.
    Shin, H. J.
    Lee, J. H.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 411 - 416
  • [40] Frontline therapy for newly diagnosed patients with multiple myeloma
    Jung, Sung-Hoon
    Jo, Jae-Cheol
    Song, Ga-Young
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    [J]. BLOOD RESEARCH, 2020, 55 : 37 - 42